Cart
sales@molnova.com
Vallesiachotamine
CAS No. 5523-37-5
Vallesiachotamine( ——— )
Catalog No. M38180 CAS No. 5523-37-5
Vallesiachotamine, a known monoterpene indole alkaloid, possesses anti-tumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameVallesiachotamine
-
NoteResearch use only, not for human use.
-
Brief DescriptionVallesiachotamine, a known monoterpene indole alkaloid, possesses anti-tumor activity.
-
DescriptionVallesiachotamine, a known monoterpene indole alkaloid, possesses anti-tumor activity.
-
In VitroVallesiachotamine induces G0/G1 arrest and increased the proportion of sub-G1 hypodiploid cells (at 11 μM and 22 μM) and this effect is not dependent on time of incubation. Vallesiachotamine acts by promoting G0/G1 cell cycle arrest, apoptosis and necrosis.
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number5523-37-5
-
Formula Weight350.41
-
Molecular FormulaC21H22N2O3
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Paula R O Soares, et al. In vitro antiproliferative effects of the indole alkaloid vallesiachotamine on human melanoma cells. Paula R O Soares. 2012 Mar;35(3):565-71.?
molnova catalog
related products
-
DSN28369
DSN28369 is a heterobifunctional linker, and useful to make antibody drug conjuate (ADC).
-
Cyclo(Gly-L-Pro)
Cyclo(Gly-(L)-Pro) shows immunostimulatory properties. Cyclo(Gly-l-Pro) exhibits potent inhibition of TNF-α release with the IC50 values of 4.5 ug/mL, respectively, it also exhibits significant diminution of IL-1β and IL-6 mRNA-expression levels and NO production.
-
PKG drug G1
PKG drug G1 targets C42 of PKG Iα. PKG drug G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism.
